Technical Analysis for SRPT - Sarepta Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 113.79 -4.83% -5.78
SRPT closed down 4.83 percent on Tuesday, February 25, 2020, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down
Historical SRPT trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish -4.83%
Bollinger Band Squeeze Range Contraction -4.83%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Duchenne Muscular Dystrophy Therapeutic Gene Modulation Antisense RNA

Is SRPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 158.8
52 Week Low 72.27
Average Volume 1,123,610
200-Day Moving Average 114.35
50-Day Moving Average 124.29
20-Day Moving Average 120.75
10-Day Moving Average 122.48
Average True Range 4.54
ADX 13.73
+DI 16.57
-DI 31.01
Chandelier Exit (Long, 3 ATRs ) 113.68
Chandelier Exit (Short, 3 ATRs ) 122.16
Upper Bollinger Band 128.13
Lower Bollinger Band 113.36
Percent B (%b) 0.03
BandWidth 12.23
MACD Line -0.38
MACD Signal Line 0.15
MACD Histogram -0.5332
Fundamentals Value
Market Cap 7.31 Billion
Num Shares 64.2 Million
EPS -2.34
Price-to-Earnings (P/E) Ratio -48.63
Price-to-Sales 53.98
Price-to-Book 6.98
PEG Ratio 231.25
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 125.79
Resistance 3 (R3) 126.78 123.76 123.79
Resistance 2 (R2) 123.76 120.71 123.27 123.12
Resistance 1 (R1) 118.78 118.82 117.27 117.79 122.46
Pivot Point 115.76 115.76 115.01 115.27 115.76
Support 1 (S1) 110.78 112.71 109.27 109.79 105.12
Support 2 (S2) 107.76 110.82 107.27 104.46
Support 3 (S3) 102.78 107.76 103.79
Support 4 (S4) 101.79